The levels of exosomal proteins vary according to the AML patients' status: the TGF-β1 level is higher in AML patients at diagnosis and in patients resistant to therapy; patients who respond to chemotherapy present lower TGF-β1 levels than patients who are resistant to chemotherapy [94]. The gene discussed is TGFB1; the disease is acute myeloid leukemia.